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Human immunodeficiency virus (HIV) infection is a serious illness that affects 
individuals, including military personnel, all over the world. If left unchecked, HIV has 
dangerous implications for a patient’s immune health, eventually progressing to Acquired 
Immunodeficiency Syndrome (AIDS). The purpose of this analysis was to determine how 
effective the U.S. military is at reaching 90% viral suppression in its HIV-positive service 
members. The main goal was to determine which factors contribute to reaching viral 
suppression. Using Kaplan-Meier survival function estimates and Cox proportional 
hazards models it was determined that service members who initiated treatment under 
more inclusive policies were more likely to reach viral suppression. The probability of 
viral suppression between services (Army, Navy, Air Force, and Marine Corps) was not 
significantly different. Identifying the factors that are important to reaching viral 
suppression in a closed military population may prove to be beneficial in understanding 
the limits of HIV transmission and its elimination through early treatment.  
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Human immunodeficiency virus (HIV) infection is a serious illness, which, if left 
unchecked, has dangerous implications for a patient’s immune health, eventually 
progressing to Acquired Immunodeficiency Syndrome (AIDS). According to recent 
surveys, the Joint United Nations Programme on HIV/AIDS (UNAIDS) estimates that as 
of 2015, almost 37 million people are living with HIV, and over two million people were 
newly infected with HIV in that year (UNAIDS 2015). UNAIDS has provided guidance 
on goals for ending the AIDS epidemic worldwide. Its most recent guidance is a program 
called “90–90-90.” In short, the three 90s in the 90-90-90 program stand for the 
following: of those individuals infected, 90% shall know their HIV positive status; of 
those diagnosed, 90% shall be engaged in highly active antiretroviral therapy 
(HAART)—the standard treatment for HIV; and of those treated, 90% shall reach viral 
suppression (where the concentration of virus in the blood is so small it decreases the 
chance of passing on the infection). The basis for their strategy is the belief that “it will 
be impossible to end the epidemic without bringing HIV treatment to all who need it” 
(UNAIDS 2014). Mathematical models have suggested that if the targets of the 90-90-90 
program are reached by 2020, the AIDS epidemic will come to a close by 2035 
(UNAIDS 2014). In addition to viral load (the measure by which clinicians determine 
viral suppression), another indicator of an HIV-infected person’s immune system is CD4, 
a white blood cell which is specifically targeted by HIV. Together, these indicators have 
historically been used to identify disease progression and when to initiate HAART. 
The U.S. military provides a unique study population to help inform policy 
regarding the 90–90-90 target. While some studies on engagement in care have been 
conducted on populations in sub-Saharan Africa (Mwesigire et al. 2015), there are no in-
depth studies of how all 3 targets are approached in the U.S. military, and how successful 
these efforts have been thus far. The U.S. military has already met the first 90, as all 
military personnel are tested regularly for HIV infection. The military has also met the 
second 90, as over 90% of patients are regularly engaged and adherent to their HAART 
regimen. Regarding the third 90, viral suppression, CD4, and viral load data are regularly 
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collected in an active surveillance program for all HIV positive service members in an 
open cohort. As such, from these data it can be determined how successful the current 
military engagement policies are at helping service members achieve viral suppression 
(Infectious Disease Clinical Research Program (ICDRP) 2015). 
The objective of this research is to answer questions about the effectiveness of 
U.S. military policies regarding care for HIV positive service members. Specifically, 
questions will be answered regarding the percentage of HIV positive patients who initiate 
antiretroviral therapy (ART), and what percentage of those who initiate ART achieve 
viral suppression. Services will initially be analyzed separately to see if there are 
differences in terms of engagement between them. Other factors will be evaluated to 
determine their effect, if any, on treatment engagement, to include demographics, 
therapeutic methods, and specific policies.  
The two main methods that will be used in this analysis are Kaplan-Meier 
estimates and Cox proportional hazards models. We set all starting times for each patient 
to t = 0, giving each patient the same starting point, and treating the population as if they 
move forward in time together. One of three things can happen to patients in these 
estimates: the patient can run out of clinical data before the full time period of the 
analysis is up (for unknown reasons); he or she can reach the outcome of interest 
(attaining a state of viral suppression); or the patient can continue to the end of the time 
period with neither event happening (survival). For each time period, the number of 
patients with available data for that time period (n.risk) and the number of those patients 
who achieve viral suppression (n.event) form a fraction estimating the likelihood a patient 
survives past that point in the cohort (i.e., does NOT achieve viral suppression), given 
that they have survived up to this time. This proportion is used for estimating the overall 
survival function of the patients in the cohort.  
Cox proportional hazards models allow us to look at all factors in a dataset, and 
see how relevant each is to the survival of patients, including interactions between the 
variables. It behaves much like a generalized linear model (glm) with β being a vector of 
coefficients corresponding to the covariates included in the model (Therneau 2015). 
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Survival functions for the time to viral suppression were estimated for a number 
of different factors, including service, treatment policy, baseline CD4 at treatment 
initiation, and PCS. There was no appreciable difference between the services. The most 
inclusive treatment policy, which allowed patients to start treatment earliest, showed the 
most positive results. Those patients whose baseline CD4 at treatment initiation was at 
least 500 showed much improvement over those who were less healthy (lower CD4 
counts). As shown in Figure 1, those individuals who were part of the most inclusive 
treatment group were more likely to reach viral suppression earlier.  
 
Figure 1. Estimated Survival Function by Treatment Policy 
 
The trends shown in Figure 1 show decreased time to reach viral suppression with 
more inclusive care  
A secondary aim of this analysis was to determine the percent of the cohort that 
reaches viral suppression. As shown in Figure 2, the treated cohort reached well over 
90% cumulative probability of viral suppression by the end of the observed time frame.  
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Figure 2. Estimated Probability of the Treated Cohort Reaching Viral Suppression 
in Each Time Step 
 
Overall, without even taking into account time, changes in treatment guidelines, 
or the many other factors in this analysis, the treated military cohort achieved about 99% 
cumulative probability of viral suppression in this 5-year study window. The estimated 
cumulative probability that the treated cohort reached viral suppression passed 90% at 
time t = 450 days.  
Next, Cox proportional hazards models were examined to determine how these 
factors contributed when placed into a model together. In the final Cox proportional 
hazards model, we found that enlisted personnel did significantly worse than officers (p 
value = 0.004), and were about 25% less likely to reach viral suppression than officers 
were. Those without an applicable rank did slightly better than officers (p value = 0.052) 
and were about 60% more likely to reach viral suppression. Being treated increased an 
individual’s chances of viral suppression significantly (p value = 0.000). Having a 
baseline CD4 between 200 and 349 did not significantly increase an individual’s chances 
of viral suppression compared to those with baseline CD4 less than 200 (p value = 
0.520). Those with a baseline CD4 between 350 and 500 were also not significantly 
different (p value = 0.349). Those individuals who had a baseline CD4 above 500 were 
almost 30% more likely to reach viral suppression than those with a baseline CD4 less 
than 200 (Estimated Hazard Ratio = 1.172, 95% C.I. (0.916, 1.497)). Those in the 
xix 
medium inclusive treatment policy were 80% more likely to reach viral suppression than 
the most restrictive policy (p value = 0.000). Those in the least restrictive policy did as 
well, being almost 80% more likely to reach viral suppression than the most restrictive 
policy, but this improvement was not significant at the 5% level of significance. 
In conclusion, no appreciable difference can be noted between the services. 
However, many important differences were found between the treatment policies, 
baseline CD4 levels, and time of treatment. These results corroborate what UNAIDS has 
put out in guidance, that early initiation of ART, regardless of CD4 count, as well as 
continuity of care, is essential to achieving a positive outcome for the patient (UNAIDS 
2014). 
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Human immunodeficiency virus (HIV) infection is a serious illness, which, if left 
unchecked, has dangerous implications for a patient’s immune health, eventually 
progressing to Acquired Immunodeficiency Syndrome (AIDS). Two main metrics are 
used to assess the state of the HIV/AIDS epidemic: prevalence and incidence. Prevalence 
is defined as what percentage of the study population has the disease (Center for Disease 
Control and Prevention (CDC) 2016a). Incidence is defined as the number of new 
infections every year. However, incidence is much harder to measure, as it is difficult to 
differentiate delayed diagnoses, which are accounted for in the prevalence estimate, from 
the truly new cases (CDC 2016a). Since incidence of new infections contributes to the 
prevalence in a population, it is likely the decline in prevalence of cases would be 
preceded by a decline in incidence (Joint United Nations Programme on HIV/AIDS 
(UNAIDS) 1999). According to recent surveys, UNAIDS estimates that in 2015, almost 
37 million people were living with HIV (prevalence) and over two million people were 
newly infected with HIV in that year (incidence) (UNAIDS 2015)  
The Joint United Nations Programme on HIV/AIDS has provided guidance on 
goals for ending the AIDS epidemic worldwide. Its most recent guidance is a program 
called “90–90-90.” The basis for their strategy is the belief that “it will be impossible to 
end the epidemic without bringing HIV treatment to all who need it” (UNAIDS 2014). 
Mathematical models have suggested that if the targets of the 90-90-90 program are 
reached by 2020, the AIDS epidemic will end by 2035 (UNAIDS 2014). An important 
part of the program is to identify populations among whom the disease is more likely to 
be transmitted. These groups are known as “at-risk populations” (UNAIDS 2014). In 
identification of at-risk populations, the incidence measure can shed light on where 
prevention efforts can be most effective. For example, in 2015, the highest rate of newly 
identified infections was in individuals ages 25 to 29, and 70% of new cases identified 
male-to-male sexual contact and/or injection drug-use as the mode of transmission (CDC 
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2016a). These data can provide important information for targeting both testing and 
information campaigns.  
The first 90 in the 90-90-90 program stands for the goal of having 90% of HIV 
positive individuals know their status (UNAIDS 2014). To achieve this by 2020, a much 
more active role must be taken in testing. Currently, in many communities, the patient 
must request HIV tests. This requires the patient to realize they are at risk and seek out 
verification for themselves. This can be problematic, especially in regions or 
communities that are not properly educated about testing and risk factors for HIV 
transmission (UNAIDS 2014). As such, more strategic targeting of at-risk populations 
must be done, and much more proactively than it has been previously.  
Once identified, individuals infected with HIV must take an active role in 
ensuring their continued health and survival. This means staying active in what is known 
as the cascade of treatment, also known as the care continuum, or cascade of care. The 
cascade of treatment includes testing and knowing one’s HIV status, beginning medical 
treatment, continued engagement in care, and ends with viral suppression (CDC 2016b). 
Engagement in care means receiving care for HIV, and viral suppression means 
achieving an extremely low number of active copies of the virus in the patient (CDC 
2016b).  
The second 90 stands for 90% of those diagnosed with HIV will receive sustained 
antiretroviral therapy (ART). The most current version of ART is Highly Active 
antiretroviral therapy (HAART). HAART has been shown to reduce the percentage of 
AIDS outcomes among patients (Cain et al. 2009). In fact, treatment with ART has also 
been shown to decrease risk of transmission between couples where one partner is 
positive, but the other is uninfected. In other words, if the HIV positive partner is treated 
with ART, they are much less likely to pass the virus on to their partner (Anglemyer et al. 
2013). This treatment provides compelling evidence that it is more effective than 
previous methods and can help UNAIDS reach its 90–90-90 goal by 2020. However, 
even though HAART may be a more effective treatment, actual sustained treatment is 
still difficult. According to UNAIDS: “ending AIDS will require uninterrupted access to 
lifelong treatment for tens of millions of people” (UNAIDS 2014). This requires a more 
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flexible and affordable infrastructure than the current system. Increasing the affordability, 
probability of success, and time needed between treatments can all aid in this effort 
(UNAIDS 2014). In areas of high infection, and low economic means, this almost always 
means the treatment must be free to the individual. 
The most common ways to monitor the success of treatment are to use CD4 
counts and viral load. CD4 is a measure of how strong the immune system is, with higher 
numbers being related to better health or a slower progression of the disease (CDC 
2016a). Viral load is the measure of the number of active copies of the virus in the body, 
with lower numbers related to better health (CDC 2016a). For the purposes of this study, 
increased CD4 counts and decreased viral load are considered indications of improved 
health in the patient. 
The third 90 represents 90% of people who receive ART go into viral 
suppression. Viral suppression means the virus is in such small concentration in the host 
that its effects are negligible and manageable. Viral suppression is a key stage in HIV 
positive patients because it opens up other possible medical procedures, and reduces the 
risk of transmission. Currently, for an HIV positive patient to be eligible for an organ 
transplant, they must either have a CD4 count above 200, or be in a stage of viral 
suppression (University of California, San Francisco (UCSF) 2013). Advances in ART 
show that, in the Latin-American countries, “80% of individuals receiving antiretroviral 
therapy … achieved viral suppression” (UNAIDS 2014). While this statistic makes it 
seem that the third 90 is already within reach, many such statistics do not account for 
mortality or attrition from the cascade of treatment. Achieving this target requires 
providers to put more effort into tracking and retaining their patients, and demands 
patients adhere to their regimens and stay engaged in the cascade of treatment (UNAIDS 
2014). 
90-90-90, while certainly an ambitious program, is not an impossible one. In fact, 
if 90-90-90 is achieved by 2020, UNAIDS predicts the AIDS epidemic will come to a 
close by 2035 (UNAIDS 2014). Just in the past few years, significant progress has been 
made in several different countries toward meeting the 2020 deadline. In Botswana, 
recent efforts to meet the 90–90-90 target resulted in 70.2% of HIV positive patients 
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achieving viral suppression (UNAIDS 2016). In fact, “new evidence in 2016 indicates 
that Sweden has already achieved 90–90-90” (UNAIDS 2016). While Sweden is 
currently the only country with documented evidence of meeting the 90–90-90 target, 
other populations are fast approaching the same goal.  
Ending the HIV epidemic worldwide carries extraordinary significance. 
Everybody would argue that healthier populations are beneficial to a society. 
Furthermore, in the context of national security, an HIV-negative military underscores 
not only the importance of healthier populations, but also highlights the strategic 
implications the implementation of 90–90-90 targets could have. In this thesis, we 
analyze how close the United States military is to achieving 90-90-90, and what factors 
have the strongest impacts on meeting these targets.  
B. BACKGROUND 
The U.S. military provides a unique study population to help inform policy 
regarding the 90–90-90 target. While some studies on engagement in care have been 
conducted on military and civilian populations in sub-Saharan Africa (Mwesigire et al. 
2015), there are no in-depth studies of how all 3 targets are approached in the U.S. 
military, and how successful these efforts have been thus far.  
The at-risk population for the military shares many of the same characteristics as 
the U.S. population at large. While 70% of the incident cases in the civilian population 
are from male-to-male sexual contact or injection drug use (CDC 2016a), the U.S. Navy 
asserts that 82% of males with HIV are infected by male-to-male sexual contact, with 
only 5% transmission from injection drug use (Navy and Marine Corps Public Health 
Center (NMCPHC) 2016a). This is to be expected, given the U.S. military’s zero 
tolerance stance on drug-use. The highest risk among demographics is among African 
Americans in both the U.S. Navy and the general population in the U.S. (CDC 2016a, 
NMCPHC 2016a). 
The U.S. military is also unique in that all active duty and Reserve members are 
screened for HIV regularly. Once every two years, every single active duty service 
member is tested for HIV (Infectious Disease Clinical Research Program (IDCRP) 
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2015a). Their positive or negative status is reported to them and their healthcare 
providers as soon as it is known (NMCPHC 2016a). As such, the first 90 target is already 
met (and surpassed) in the U.S. military, as 100% of active duty service members are 
tested and aware of their HIV status. In fact, initial screening for HIV is done before 
civilians enter service, so this testing also makes some members outside the military 
aware of their HIV status as well. With this important target in the 90–90-90 goal already 
reached, it is possible to look more closely at the next two.  
The military stands on good footing to achieve the second 90: initiation of ART. 
All service members have access to free healthcare, and receive regular checkups, at 
minimum, once every year, to evaluate their overall health. Per Department of Defense 
Instruction (DoDI) 6025.19, these checkups are mandated, and each command ensures its 
service members are making use of these services as needed (Department of Defense 
(DOD) 2014). As previously mentioned, free access to ART and regular engagement in 
care is key to achieving viral suppression. This potentially high rate of ART initiation 
among HIV-infected service members indicates that the second 90 target has already 
been met. 
Regarding the third 90, viral suppression, CD4 count and viral load data are 
regularly collected in an active surveillance program for all HIV positive service 
members in an open cohort. As such, from these data, it can be determined how 
successful the current military engagement policies are at helping service members 
achieve viral suppression (ICDRP 2015b). 
C. OVERVIEW 
This study uses the largest repository of active duty military HIV infection data in 
existence. The cohort, since its establishment in 1986, has enrolled nearly 6,000 active 
duty members, and has over 1,500 active participants (IDCRP 2015a). The current 
dataset contains multiple visit data for each patient, and recorded CD4 counts and viral 
load measurements and, when available, outcome results.  
The population of interest includes all members of the current cohort, which 
includes active duty service members and any of their beneficiaries who are infected with 
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HIV. The longest record in the current dataset spans over 3,700 days. Demographic data, 
as well as engagement and clinical information, are available for the participants, of 
which, the clinical data are identified by date.  
D. PROBLEM STATEMENT 
HIV infection is a serious concern of the U.S. military. Air Force Instruction 
(AFI) 44–178 mandates that HIV positive service members must have constant access to 
treatment and care (Secretary of the Air Force [SECAF] 2014). In the Department of the 
Navy alone, an active duty sailor or Marine is infected with HIV about once every 4 days 
(NMCPHC 2016b). Most of the time, the service members are allowed to remain on 
active duty, unless their health deteriorates to where they can no longer perform their 
duties. However, enlisted service members who have tested HIV positive while in service 
lose access to commissioning programs (NMCPHC 2016a), robbing the military of 
potential officers, and limiting career flexibility of promising individuals. 
As late as 2010, HIV policy prohibited HIV positive service members from being 
assigned to deployable units (NMCPHC 2010). This policy was recently changed to 
allow those HIV positive members in good health to be assigned to operational units 
(NMCPHC 2016b). However, this is on a case-by-case basis, and depends entirely on 
how healthy the service member is. As such, engagement in care and viral suppression 
are key to maintaining operational effectiveness and retention of qualified service 
members. 
Thomas et. al. (2014) studied military populations in sub-Saharan Africa and 
found that all HIV positive service members seroconverted (became HIV positive) after 
entering the service. The authors found that most countries allowed their HIV positive 
members to be deployed overseas, and required regular testing of active duty members 
for HIV. However, another study of data from the South African National Defense Force 
(SANDF) revealed that the South African military is losing at least 400,000 working days 
a year due to HIV infection (Health Systems Trust (HST) 2004). While the U.S. military 
is not in as serious a predicament, HIV infection poses a risk to operational availability 
and readiness.  
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E. OBJECTIVE 
The objective of this research is to answer questions about the effectiveness of 
U.S. military policies regarding care for HIV positive service members. Specifically, 
questions will be answered regarding the percentage of HIV positive patients who initiate 
ART, the frequency of gaps in treatment, and what percentage of those who initiate ART 
achieve viral suppression. Services will be analyzed individually to see if viral 
suppression differs between them. Other factors will be observed to determine their 
effect, if any, on frequencies of engagement, to include demographics and specific 
policies.  
F. SCOPE AND OUTLINE 
The data used in this thesis are from the “U.S. Military HIV Natural History 
Study” (NHS), and include HIV cases of active duty military and their infected 
dependents from 2008 to 2015. The prospective cohort that will be used to answer these 
research questions is drawn from this population. Included in this cohort are active duty 
service members enrolled from 2008 to 2015, excluding subjects with less than one year 
of follow up (IDCRP 2015a).  
This thesis analyzes the engagement in HIV care in the U.S. military population, 
with a particular focus on the differences in care between services, to include 
centralization of models of care, and demographic or operational differences. The 
cascade of engagement defined in this study includes infection, diagnosis, linkage to care, 
retention in care, initiation of ART, and viral suppression. The main outcome variable 
will be viral suppression. The two main tools used will be survival analysis with Kaplan-
Meier and Cox proportional hazards models (Diez 2013). 
Chapter II gives a detailed introduction to the current military policies, the study 
cohort, prior analyses, and the statistical methods used in this thesis. Chapter III describes 
the data and methods of analysis used, as well as some brief descriptive statistics. Chapter 
IV lays out all results from the analyses, and briefly describes the meanings of each 
result. Chapter V gives a more detailed explanation of the implications of these results, 
and recommendations for future work.  
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II. DATA INTRODUCTION  
A. CURRENT MILITARY POLICIES 
Since the HIV epidemic began, “over 10,000 active duty military members have 
been diagnosed with HIV infection” (IDCRP 2015a). Each service in the U.S. military 
has its own guidelines regarding the treatment of HIV positive individuals, apart from the 
Marine Corps, which falls under Navy policy. While all policies recognize and reference 
the authority of national standards for HIV treatment, each service has different standards 
and levels of specificity for how to track engagement and clinical outcomes of their HIV 
positive patients. All policies condition the individual’s retention in service on their 
ability to perform their duties, and access to necessary medical care.  
All services acknowledge the precedence of national HIV treatment standards, as 
developed by the National Institutes of Health (NIH) and as such are nonspecific on 
treatment procedures or medication regimens. The NIH and World Health Organization 
(WHO) release guidelines for HIV care and updates them when new data or studies are 
available. Before 2009, the WHO recommended starting ART if a patient’s CD4 count 
dropped below 200, or initiating when they came close to such a level, to prevent their 
CD4 counts going any lower (WHO 2006). Gradually, the treatment policies have 
become more inclusive, allowing patients with higher CD4 counts to begin treatment 
(WHO 2010, 2013, 2015). In fact, current NIH recommendations state that ART should 
be initiated immediately in all patients, regardless of age or CD4 count (NIH 2016). 
Regarding specific medications, there are many regimens and specific drugs from 
which to choose, but there is a standardized regimen for those patients just beginning 
ART, known as “treatment-naïve” patients (NIH 2016). According to NIH, “more than 
25 antiretroviral (ARV) drugs in 6 mechanistic classes are Food and Drug Administration 
(FDA)-approved for treatment of HIV infection.” (NIH 2016). Among the classes of 
these drugs are nucleoside/nucleotide reverse transcriptase inhibitors (NTRIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion 
inhibitor (FI), integrase strand transfer inhibitor (INSTIs), and pharmacokinetic (PK) 
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enhancers, which are used to increase the effectiveness of other medications in the 
regimen. The current standard regimen for treatment-naïve patients is two NRTIs, plus an 
INSTI, NNRTI, or PK-enhanced PI. This regimen has been shown to increase CD4 
counts in new patients (NIH 2016). The differences between these drugs, as well as their 
mechanisms and drug interactions, are beyond the scope of this thesis. For the purposes 
of this thesis, the drugs are assumed to have been administered correctly by the 
healthcare provider.  
The U.S. Air Force details its guidelines for treatment in AFI 44–178 (SECAF 
2014). The Air Force mandates, once an individual has tested positive for HIV, that the 
service member be counseled as soon as possible. A health evaluation is done upon the 
initial visit, as treatment is discussed and initiated. Six months after the initial visit, 
another evaluation is required to assess progress, after which, evaluations are mandatory 
every twelve months (SECAF 2014). The policy details that these visits are required, but 
not the only appointments which should be made, saying other clinical visits as part of 
the treatment regimen should be conducted as well. The policy also details that, should a 
service member show signs of psychiatric distress or deterioration as a result of the 
disease, they should receive the appropriate care. The policy mandates additional testing 
“as indicated to maintain compliance” (SECAF 2014). 
The U.S. Navy is the most general in its guidelines regarding HIV treatment and 
engagement. The policy, Secretary of the Navy Instruction (SECNAVINST) 5300.30E, 
requires the frequency of evaluations to be determined by “health status” and “nationally 
accepted guidelines” (SECNAV 2012). The Navy also requires an evaluation of the 
individual’s potential for transmission, mandating counseling for the patient’s sexual 
partners, and evaluating any risks of exposure for other individuals the patient may have 
come into contact with (SECNAV 2012). 
The U.S. Army has the most detailed guidance regarding care for HIV positive 
individuals. Army Regulation (AR) 600–110 mandates that after the initial positive test, 
the patient’s commanding officer is immediately notified and required to counsel the 
patient face to face (Personnel General 2014). They are required to read a document 
detailing that individual’s new obligations, risks, as well as restrictions, such as not 
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donating blood (Personnel General 2014). After the initial counseling, that individual is 
required to attend a psychiatric evaluation to determine their current state, and to provide 
a baseline in case of neurological deterioration due to the disease. After these initial 
evaluations, and in addition to all their regularly scheduled medical appointments for 
treatment, the soldier is required to receive a clinical evaluation twice yearly. Their 
commanding officer is notified of any noncompliance issues (Personnel General 2014). 
B. COHORT INTRODUCTION 
Combining all patients from each service, the NHS is a study under the IDCRP. 
The main goal of this work is to generate data and physical samples which can be 
referenced in many future studies. The program has several strategic aims which guide 
their research. This thesis, with its focus on engagement in care and on outcomes for 
active duty patients, focuses mainly on aims 1 and 2, as shown in Figure 1.  
 
Figure 1.  U.S. Military Natural History Study (NHS) Strategic Aims.  
Source: IDCRP (2015a). 
The NHS has assembled a cohort of patients, whose demographic and clinical 
data, as well as tissue and serum samples, are collected and retained for future studies. 
Since 1986, over 6,000 active duty military members or their beneficiaries have 
participated in the NHS cohort. Currently, about 1,500 members of the cohort are still 
actively participating in data collection and sampling. This current cohort is racially 
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diverse, and nearly half were on active duty as of their last visit. Figure 2 shows the racial 
diversity of the patients who are currently active in this cohort. 
 
Figure 2.  Racial Demographics of the Current NHS Cohort Study Source: IDCRP 
(2015b). 
 
Figure 3.  Career Status of the Current NHS Cohort. Source: IDCRP (2015b). 
Figure 3 shows that the largest portion of the dataset comes from active duty 
members of the U.S. Military, with only a small number of the cohort being civilians, 
such as DOD service member beneficiaries. Currently, the NHS has three main research 
interests. First is the study of HIV outcomes, to include AIDS, cancer, neurocognitive 
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effects, and others. Another interest is on treatment outcomes, such as the outcome of 
ART, and any complications and costs associated with the treatment. Third is the 
epidemiology and prevention of HIV and other sexually transmitted infections (IDCRP 
2015b). 
To aid in these research interests, many types of data have been collected on the 
current cohort. Demographic data, to include age, gender, race, ethnicity, duty status, 
military specialty code, rank, marital status, and more, have been collected for each 
patient. Of particular interest to this research study is adherence data, which includes 
appointment test dates and pharmaceutical refill data (IDCRP 2015b). The dataset also 
includes medication regimen information as well, detailing which drugs the patients were 
treated with, and when (IDCRP 2015b). ART has been shown to be very effective when 
used correctly (UNAIDS 2014). As such, this study assumes correct implementation of 
ART. To judge the effectiveness of patient care, this study focuses on length of treatment 
and indicators of health, such as CD4 and viral load data. Also collected are clinical data, 
such as CD4 counts, CD8 counts (CD8 is a white blood cell similar to CD4), and viral 
load measures for each patient. The data are collected through in-person interviews, 
medical records, questionnaires, and automatic captures from online military health 
systems (IDCRP 2015b). 
C. PRIOR ANALYSES 
This dataset has been used to conduct other analyses. Marconi, et al. (2010) 
provided insights on the outcomes of ART combined with the effects of universal 
healthcare. In this study, the active duty cohort’s viral load and clinical outcomes (AIDS, 
death, or none) were evaluated to determine how effective ART is when implemented in 
a population which has universal access to healthcare. The study showed that active duty 
rates of viral suppression and desirable outcomes were higher than other populations, and 
so it is likely that increased access to healthcare is an aiding factor in viral suppression. 
Previous work on engagement in care in the military has been done by Mancuso 
(2016) with a subset of the data used in this thesis. Many of the concepts addressed in this 
thesis stem from this study. Mancuso (2016) provided some general descriptive statistics 
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of the study population, as well as data concerning the overall cascade of care data, and 
viral suppression timelines in his analysis. Some questions left unanswered by Mancuso 
(2016) were how HIV engagement differs by service, and what factors effect 
engagement.  
D. STATISTICAL METHODS 
Three main approaches were used to obtain the results of this study: descriptive 
analyses using unadjusted percentages, and survival function estimation using Kaplan-
Meier estimates and Cox proportional hazards models.  
1. Constructed Variables 
To aid in the analysis, several variables were constructed or transformed from the 
given data. First, a discrete time variable was created, which ranged in value from 1 to 
20, with each time representing a single 90-day increment from the date the patient was 
documented as HIV positive. This served to give all patients the same starting point in 
terms of known HIV status.  
A variable named PCS was created, which indicated how many times the patient 
moved or made a Permanent Change of Station (PCS) while undergoing treatment. Each 
patient’s PCS variable starts at 0, indicating this location is the first they have lived in 
since their diagnosis. When a patient makes a PCS, the PCS variable increments to 1, 
showing it is their first move since diagnosis, and so on. The PCS variable reaches values 
as high as 4 for some patients, indicating four moves since diagnosis. 
To assess how a patient’s ART treatment was implemented, several treatment-
related variables were constructed. Time_TX, a variable, ranging from 1 to 20, indicates 
in which 90-day time period the patient began to receive ART. TX, a similar variable, is a 
binary with 0 signifying the patient is not being given ART, and a 1 indicating they have 
started to receive ART. Next, Met is a binary variable, which indicates if the patient’s 
treatment at the time met (adapted) WHO HIV treatment initiation guidelines, or not. We 
acknowledge that the HIV treatment guidelines are a bit more nuanced than simply using 
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a CD4 indicator, to include AIDS-defining illnesses etc., WHO (2006, 2010, 2013, 2015). 
The adapted treatment initiation guidelines are laid out in Table 1:  
Table 1.   Treatment Guidelines for Starting ART in HIV+ Patients Adapted 
from World Health Organization (WHO) (2006, 2010, 2013, 2015). 
Policy: End Date: 
CD4 < 200 Nov-09 
CD4 < 350 Jan-13 
CD4 < 500 Sep-15 
Treat All Patients Current 
 
For the Met variable to be 1, indicating compliance with treatment guidelines, 
either the patient must have been treated with ART, or, if they were not, they must have 
exceeded the minimum CD4 count needed to begin treatment, as defined by the policies 
above. The variable TX_GROUP indicates which policy each patient began treatment 
under, ranging from 1, being the policy which was ended in November of 2009, to 4, 
being the current policy to treat all patients regardless of CD4 count. All patients in this 
cohort who began treatment fall into the first three categories, with no patient starting 
ART under the current policy.  
Next, the age demographic variable was transformed into a factor with six levels, 
starting at under 20 then going up in five year increments until over 40. In addition, from 
CD4 measurements and time_TX, the variable BASE_CD4 was created, indicating the 
CD4 level of the patient at the time they started ART treatment. From the available 
adherence data in this cohort, calculated as the percent of doses of medication a patient 
took on time, the average adherence of each patient over the twenty quarter timeline was 
calculated. From this average adherence data, two binary variables were created: 
ADHERE_90 and ADHERE_95, which are zero if a patient’s average adherence falls 
below the threshold (90% and 95%, respectively) and one if they meet or exceed the 
threshold.  
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Lastly, an outcome variable, or event of interest variable, was created: VS. This 
variable is a zero for each individual patient until the first time their viral load falls below 
200, at which point it changes to 1 and remains 1 from there on. Viral suppression is a 
positive outcome, therefore patients who “survive” longer in the dataset and do not reach 
this state are considered to be in a worse health than those who reach viral suppression.  
2. Unadjusted Percentages 
To gain insight into the general trends throughout the data, mean values and 
percentages were computed. In the case of a missing value or null value, such 
observations were removed from the calculation. Racial and background demographic 
variables are recorded once per patient, while clinical variables can be recorded several 
times per patient, one for each encounter in which the variables were recorded. The 
clinical data were not normalized to provide an equal contribution per patient because 
patients with more clinical data are considered more informative to this study, and so 
have a larger influence on the initial descriptive statistics.  
3. Kaplan-Meier Survival Analysis  
For Kaplan-Meier estimates of the survival function, all patients are treated as if 
they entered at the same initial time (t = 0), and are removed from the number “at risk” 
(n.risk) as the event of focus occurs to them or if they are censored. The function S(t) is 
the probability that in individual “survives” to time t. It is estimated based upon how 
many individuals are at risk and how many of those individuals experience the event of 
interest up to time t. Specifically, let 0< t1 < t2 < …< tm be ordered observed “death” (or 
event) times, and let n.riski and n.eventi (i = 1, … m) be, respectively, the number of 
individuals at risk, and the number of events to occur among those at risk at or before 
time ti. Then, for right-censored data, the Kaplan-Meier estimator of S(t) is given by:  
1
1
1                                  if 
ˆ( ) .
















The specific event used can be any binary event of interest to the researcher. In 
this study, the outcome of interest is viral suppression. Each patient receives a zero for 
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the outcome variable while they are still in the dataset, but as soon as they reach viral 
load below 200 cells per microliter, they are counted as a one, i.e. the event of viral 
suppression has occurred. As such, survival in the model is associated with a negative 
outcome – still being sick, while a “death” in the model actually represents a positive 
outcome for the patient.  
This particular dataset includes what is known as “right-censoring”, meaning data 
collection may stop (for reasons unrelated to the outcome event) before viral suppression 
is reached. In such cases, data for a particular patient is no longer available, so they are 
removed from the at risk group. This right-censoring is not counted as an event of 
interest, but does decrease the total remaining in the cohort, and as such means 
confidence intervals will widen with decreased cohort sizes as time progresses.  
4. Cox Proportional Hazards Analysis 
Cox proportional hazards models allow the survival function to be a function of 
covariates (see Diez 2013). Let z be a vector of covariates and let β be a corresponding 
vector of parameter coefficients. The conditional hazards function is 
( | ) log ( | )H t S t z z  where S(t|z) is the survival function given covariates z. The Cox 
proportional hazards model is a semi-parametric model where the hazards given 
covariates z, is proportional to a baseline hazards, H0(t):  
0H( | ) ( )exp{ }    0t H t t z β'z  
Both H0(t) and β are estimated and, like the Kaplan-Meier estimator, those 
estimates can be based on right censored data. We note that this definition of the Cox 
proportional hazards model requires that the covariates be time independent (e.g., sex, 
service, etc.) However, the Cox proportional hazards model can be extended to include 
certain time varying covariates (e.g., rank, age, etc.)  
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III. DATA AND METHODOLOGY 
A. DATA DESCRIPTION 
This thesis uses data from a cohort made up of HIV-infected military service 
members. Every individual has all demographic, clinical, and encounter data points 
stored along with a de-identified variable called “MUCKED_PIN,” by which they are 
identified for the remainder of their participation in the cohort.  
The data were processed by the primary investigators at the NIH in Bethesda, 
MD, to ensure the sample was complete, and de-identified. The processed dataset has 904 
cohort participants. The data were contained in 11 comma-separated value spreadsheets. 
Each spreadsheet contains a different aspect of the dataset. One contains all CD4 counts 
and dates from patient tests, and two contain demographic information. The first 
demographic spreadsheet contains data regarding gender, rank, first diagnosis, first and 
last visits, death, etc. The second contains data related to the mode of transmission. 
Another two spreadsheets contain doctor-patient encounter data, including the date of 
each appointment, the doctor’s diagnosis, represented by an ICD9 code, as well as the 
method by which the patient received medication. Two spreadsheets contain information 
related to the ART each patient is undergoing. They detail which medications the patient 
is taking, in what quantities, the medicinal class of the prescriptions, and binary variables 
indicating presence or absence of each of the main types of prescription regimens. One 
spreadsheet contains adherence data, describing the visit date by the patient, and the 
percent adherence to the medication regimen. Two more sheets give PCS data for each 
patient, describing if they PCS’ed during treatment, and how many times. Lastly, there is 
also a spreadsheet with the viral load results of each patient’s tests, containing multiple 
entries per patient, one for each test conducted. There are also two definition spreadsheets 
which describe the abbreviations and codes used for each of the variables. 
B. DATA ELEMENT DESCRIPTIONS 
The original dataset contains 133 variables, though the variables of most interest 
as they pertain to our research questions are variables detailing relative health, such as 
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CD4, CD8, and viral load, and variables detailing engagement such as adherence data and 
appointment information. Also of interest are demographic data such as race, rank, and 
gender.  
1. Maximum CD4, CD8, and Viral Load Count by Time 
For every test a patient submits, CD4 counts are recorded. Dates of the tests vary 
widely, sometimes with several tests over a couple of months, and sometimes with no 
tests for several months at a time. As such, a standardized time unit was created, with a 
division every 90 days. The zero date for each patient is the date of their first positive 
diagnosis (day zero). When tests are conducted, they fall within 90-day divisions of 
separation from day zero. For each patient, the maximum value of their CD4 count was 
taken for each 90-day increment, for 20 such increments, which provides roughly 5 
years-worth of time steps for analysis. If a patient does not have data for one of the time 
steps, the result is assigned an NA value, where NA indicates a missing value. As such, a 
dataset was created which contained maximum CD4 values for time steps (i.e., 90-day 
windows) 1 through 20 for every patient. The same methods were applied to create 
similar variables for CD8 count and viral load. 
2. Background Demographics 
Each patient was labeled with one of 6 categories of racial background: White, 
African American, Native Hawaiian or Pacific Islander, Asian, American Indian or 
Alaska Native, or other. A binary variable indicates male or female. Marital status data 
were available, having the following levels: not married, married – living together, 
married – not living together, married – living apart – not separated, married – separated, 
widowed, divorced, and not married – living together (cohabitative).  
3. Military Demographics 
Military specific data were collected on each patient. Each patient’s rank at 
diagnosis is recorded as officer, warrant officer, enlisted, N/A (where N/A denotes “not 
applicable”), or missing. No further resolution, such as individual enlisted or officer 
ranks, is given, so it is impossible to tell the exact rank of the patients. Each patient’s 
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service affiliation is also recorded as Army, Navy, Air Force, Marines, or Coast Guard. 
While Coast Guard is included as a possible level for the variable, no Coast Guard 
patients exist in this dataset. Each patient’s duty status at diagnosis was also available; 
however, the variable is largely irrelevant, as all 904 members of the cohort were on 
active duty at the time of diagnosis. 
4. Risk Factor Variables 
Risk behaviors based upon patient surveys were also available. Risk of alcohol 
abuse was a trinary variable: no use, not at risk, or at risk. Smoking was a binary variable: 
yes or no. Other risk factors included the possible method of transmission, which is based 
upon patient surveys regarding activities they admit to engaging in which carry with them 
high-risk for HIV transmission. The levels of the mode of transmission variable include 
unknown, same sex intercourse, opposite sex intercourse, blood products, injection drugs, 
or other. It should be noted that mode of transmission data can contain multiple responses 
for each patient, as it does not identify for certain how the patient was infected, but 
identifies the risk behaviors which the patient reports engaging in which could have led to 
infection. 
5. Clinical Variables 
Each patient has a year of positive diagnosis listed, along with their date of 
diagnosis. Each patient also has an estimated year and date of seroconversion 
(seroconversion is the time at which HIV reaches high enough levels in the body to be 
detectable in a HIV test). Other variables include the number of drugs each patient was 
on during treatment, as well as the class of each drug, and the specific name and type of 
the drug. Another variable available for each patient is adherence data, usually calculated 
by the medical provider, who counts how many medication doses the patient missed over 
the course of their prescription. 
C. DESCRIPTIVE STATISTICS 
Based upon the variables described above, general trends in the data can be 
summarized. The make-up of the cohort can be compared with the rest of the military 
 22 
population. There are several key similarities and differences, which are highlighted 
below. The clinical outcomes are also summarized below, giving a general idea of the 
overall health and effectiveness of care in the study population.  
1. Cohort Profile 
To determine the demographic profile of the cohort and how it compared to the 
rest of the military, the background demographics were analyzed for similarities and 
differences, starting with racial background shown in Figure 4.  
 
Figure 4.  Racial Profile of the Study Cohort 
While Figure 2 covers the entirety of the IDCRP working group, from 1996 to the 
present, Figure 4 only considers those patients who are included in the subset of the 
cohort, which is used for this analysis. From these basic statistics, it is evident there is a 
disparity between the study cohort and the rest of the military. The majority of the U.S. 
military (70.7%) is White (DOD 2015), while in this dataset, the inverse is true, with 
Whites making up only 33% of the total cohort. The largest population in the study is 
African Americans, at 44%, whereas they only make up about 17% of the total military 
force (DOD 2015). Asian service members make up 4% in both the total force and this 
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as well. Native Hawaiians and Pacific Islanders only make up about .9% of the total 
force, while in this study, they make up a disparate 14% of the study cases.  
Regarding gender, there is a disproportionate number of male members of this 
cohort to females—97% of the cohort is male, with 3% female. In the rest of the military, 
84.5% are male and 15.5% are female (DOD 2015).  
Statistics for the total military force only have variables for never married, 
married, or divorced, as such, the statistics of this cohort were combined to make a 
comparison. Firstly, 65.2% of the study cohort is single, 28.1% is married, and 3.4% is 
divorced, versus the total military force which is 54.3% married, 41.6% never married, 
and 4.0% divorced. There is a much higher percentage of single members of the cohort 
than in the military at large (DOD 2015).  
2. Military Profile 
Regarding military-specific statistics, the officer-enlisted ratio is similar to the 
total military force. The cohort contains 11% officers and 88% enlisted, while the 
military at large contains 17.7% officers and 82.3% enlisted (DOD 2015). 
However, this similarity ends when viewing the service branch. While the regular 
military is composed of about 37.4% Army, 24.8% Navy, 14.1% Marine Corps, and 
23.6% Air Force (DOD 2015), the cohort is composed of almost half Navy, 20% Army 
and Air Force, and only about 10% Marine Corps, as shown in Figure 5. 
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Figure 5.  Service Affiliation of the Study Cohort 
It should be noted how disproportionately represented the Navy is in the HIV 
positive cohort, accounting for almost half of the study population, while the regular 
Navy only accounts for about one fourth of the total military. 
3. Clinical Profile 
According to the CDC, in 2011, 24% of active duty military members reported 
smoking, versus 27.1% in this study cohort (CDC 2017). A 2008 study found that “20% 
of military personnel reported binge drinking every week in the past month” (NIH 2013). 
While metrics change over time, in this study cohort, 27% of participants were 
considered at risk for alcohol abuse, 67.5% reported using alcohol, but were not 
considered at risk, and 22.5% reported no alcohol use.  
Continuing with risk behaviors, the majority of participants (64.8%) were of 
“unknown” mode of transmission. This could be because of missing data, or because 
patients declined to respond. As noted before, this metric allows for multiple responses 
from each patient, and assesses risk activities associated with HIV infection, so actual 
mode of transmission cannot be known for each patient. However, of those who 
responded in the cohort, 24.6% listed same sex intercourse as a possible mode of 






Army Navy Air Force Marines
 25 
“other.” Only 0.2% of the cohort listed injection drug use as a possible mode of 
transmission, which is to be expected, considering the military’s zero tolerance policy on 
illicit drug use.  
Each patient’s adherence data contain multiple doctor visits in which percent 
adherence is measured. These data contained 5056 individual observations for the 907 
patients in the cohort. The data were not separated or averaged by individual, as total 
adherence per visit was of interest, rather than average adherence by patient. The data 
were divided into several increments, and total counts were calculated for each 
increment, as shown in Figure 6. 
 
Figure 6.  Adherence Data of the Study Cohort  
Seventy-two percent of the responses indicated 99% or greater adherence to the 
regimen, 92.2% of the responses indicated 90% or greater adherence, meaning only 7.8% 
of the responses were less adherent. 
4. CD4, Viral load, and Viral Suppression 
90-90-90 specifies that out of the population, 90% should know their status, of 
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should reach viral suppression. As such, closer analysis of the study population, to 
separate adherent and non-adherent patients, would aid in analysis of how close to 
reaching the target the U.S. military truly is. However, to get a general view of how 
patient health changes over time, in this section we study changes in CD4 levels, viral 
load, and viral suppression over time, excluding missing values. Time zero for each 
patient was considered to be their documented positive date, as such, the date of time 
zero is different for every patient, but clinically speaking, each patient should be in 
relatively the same state at such a time because of the regular HIV tests service members 
need to receive. We note that each patient’s record contains an estimated seroconversion 
date (i.e. the earliest date that HIV antibodies could be detected). As shown in Figure 7, 
HIV positive results rarely come later than one year after seroconversion.  
 
Figure 7.  Time from HIV Seroconversion to Diagnosis  
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The average time from estimated seroconversion to documented positive dates is 
249 days, though there are some extreme outliers well beyond the 1, 2, and even 3 year 
marks. However, without patient-specific data, it is impossible to exactly determine the 
reason for such long intervals. It should be noted that the majority of patients contained in 
the dataset were identified quickly. 
 
Figure 8.  Average Maximum CD4 Count over Time in the Continuum of Care  
In Figure 8, we plot the average value of all patients’ maximum CD4 value over 
time (excluding patients with missing values). As the patients pass through the continuum 
of care, average maximum CD4 counts tend to increase, indicating a healthier immune 
system. While this graph looks like compelling evidence for effectiveness of treatment, 
more treatment data are needed before more robust conclusions can be drawn. However, 
on a preliminary basis, these data appear to indicate effective treatment and increased 
patient health along the continuum of care.  
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Viral load data were handled much like CD4 data, with one important difference 
in interpretation. While maximum CD4 values provide a best-case estimate of patient 
health, maximum viral load values provide a worst-case estimate of patient health. 
However, as can be seen from Figure 9, both tell the same story of improved patient 
health with increased time in system. Before a patient begins treatment, there is very little 
to restrict the virus from multiplying, as such, at time zero, viral load is extremely high, 
and decreases dramatically once treatment starts, and continues to decrease, indicating a 
trend in improved patient health over time. 
 
Figure 9.  Viral Load over Time 
Since viral load seems to be decreasing, the data were inspected to see what 
percentage of patients reached viral suppression within the given time frame. Enough 
patients did reach suppression to warrant a descriptive graph of the trend, shown in 
Figure 10: At time zero, no patients are in viral suppression; however, as treatment 
progresses, the percentage who are in viral suppression increases. 
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Figure 10.  Proportion of Viral Suppression in the Cohort over Time 
The data used in Figure 10 includes patients who were treated and untreated. To 
gain a more accurate estimate of the proportion of the cohort who are suppressed in a 
given time frame, only patients who were not missing for that time frame were included, 
as a preliminary method to account for lack of data as time progresses. For this analysis, 
the common threshold of viral load less than 200 counts per microliter was used to 
indicate suppression.  
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IV. RESULTS AND ANALYSIS 
A. EXPLORATORY SURVIVAL ANALYSIS 
Survival analyses using Kaplan-Meier and Cox proportional hazards estimates of 
the survival functions were performed from the “survival” package (Therneau 2015) in R 
(R Core Team 2016). An object of class “Surv” was created using the “Surv” function. 
The time index used was the “time” variable in the dataset, and the outcome variable was 
the “VS” binary variable from the dataset. VS =1 indicates the person going into viral 
suppression, otherwise, VS = 0. Therefore, longer “survival” in the at risk group is a 
negative outcome, while attaining viral suppression and dropping from the at risk group 
is a desirable outcome. In this survival analysis, the data can be right censored. Of the 
904 patients in the analysis, 789 achieved viral suppression by time t = 20 (1800 days). 
Of the other 115 patients who never reached viral suppression, 37 of them remained in 
the at risk group at time t = 20. As such, 78 out of the 904 patients are right-censored 
without a known reason. Because patients are not removed from the at risk group for 
health or treatment reasons, we assume right censoring is independent of viral 
suppression times. One major assumption of the analysis was that, if a patient’s viral 
suppression status was not known for a given time period (but the patient was known to 
still be part of the study cohort i.e. had data for later time periods), VS was set to zero. As 
such, a patient could possibly have reached viral suppression in an earlier time period in 
which data was not available, but they are not counted as such until the event is known. 
Thus, all estimated survival functions for the time until viral suppression give a 
conservative upper bound. In this section, we look at differences in survival functions for 
each variable, one at a time. While separation by one variable at a time cannot give a 
complete picture of interactions between the factors available in the data, it serves as an 
exploratory analysis to identify potentially important variables and begin to understand 
how each factor effects survival.  
1. Survival Functions by Treatment 
We first estimate the survival function as a function of the variable “TX” for 
treatment. Of all patients in the dataset, 828 were treated, and 76 were never treated. Also 
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of note in this section is how patients move between the two groups. A patient may be 
untreated for some time periods, and begin treatment later, at which point he or she 
moves to the at risk group in the treated cohort. As such, the number at risk in the treated 
cohort may increase as time progresses. However, never will a patient move from treated 
to untreated. For the plotted estimated survival functions with time-dependent variables, 
individuals are assumed to remain in the cohort in which they started, rather than moving 
between groups as they do in the survival function estimate tables.  
 
Figure 11.  Estimated Survival Function of Viral Suppression Times by 
Treatment with 95% Confidence Intervals (Dotted Lines) 
The estimated survival functions for viral suppression time by treatment plotted in 
Figure 11 display the expected results: those who are treated for their disease have a 
higher chance of attaining a desirable outcome early—viral suppression—while those 
who go untreated remain at much higher risk for negative outcomes.  
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Table 2.   Estimated Survival Function of Treated Individuals 
Treated 
t n.risk n.event ˆ( )S t  
90 328 26 0.921  
 (0.886 , 0.945) 
180 420 181 0.524  
 (0.476 , 0.569) 
270 301 175 0.219  
 (0.185 , 0.255) 
360 162 56 0.144  
 (0.117 , 0.173) 
450 152 64 0.083  
 (0.065 , 0.104) 
540 117 47 0.050  
 (0.037 , 0.065) 
630 97 35 0.032  
 (0.023 , 0.043) 
720 86 28 0.021  
 (0.015 , 0.03) 
810 73 25 0.014  
 (0.009 , 0.02) 
900 61 18 0.010  
 (0.006 , 0.015) 
990 55 14 0.007  
 (0.005 , 0.011) 
1080 54 17 0.005  
 (0.003 , 0.008) 
1170 56 14 0.004  
 (0.002 , 0.006) 
1260 49 14 0.003  
 (0.002 , 0.005) 
1350 42 12 0.002  
 (0.001 , 0.003) 
1440 38 9 0.001  
 (0.001 , 0.003) 
1530 37 9 0.001  
 (0.001 , 0.002) 
1620 31 4 0.001  
 (0.001 , 0.002) 
1710 35 5 0.001  
 (0 , 0.002) 
1800 31 6 0.001  
 (0 , 0.001) 
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Table 2 shows the estimated survival function by time period for all treated 
individuals in the cohort. The time dependency of this variable is readily apparent, as the 
number treated at risk increases from time t = 1 (90 days) and t = 2 (180 days). The 
chance that a treated individual remains non-virally suppressed decreases quickly, until 
survival nearly reaches zero by the end of the period of observation.  
Table 3.   Estimated Survival Function of Untreated Individuals 
Untreated 
t n.risk n.event ˆ( )S t  
90 576 19 0.967  
 (0.949 , 0.979) 
180 439 1 0.965  
 (0.946 , 0.977) 
270 383 10 0.940  
 (0.914 , 0.958) 
360 335 5 0.926  
 (0.897 , 0.946) 
450 283 4 0.913  
 (0.881 , 0.936) 
540 249 2 0.905  
 (0.872 , 0.93) 
630 219 1 0.901  
 (0.867 , 0.927) 
810 181 2 0.891  
 (0.854 , 0.919) 
900 164 2 0.880  
 (0.84 , 0.911) 
990 149 3 0.863  
 (0.817 , 0.898) 
1260 107 1 0.854  
 (0.806 , 0.892) 
1440 91 1 0.845  
 (0.793 , 0.885) 
1620 79 1 0.834  
 (0.777 , 0.878) 
 
Table 3 shows the estimated survival function by time period for individuals who 
are not given ART. The untreated cohort fares significantly worse than the treated one. 
Survival in the at-risk population is almost the inverse of the treated population. About 
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80% of those who are never treated are estimated to remain non-virally suppressed by the 
end of the observed period. Note how quickly the number at risk diminishes, due to 
patients moving to the treated cohort, but how few events of viral suppression occur for 
the untreated individuals, leaving their survival relatively high by t = 20 (1800 days).  
2. Survival Rates by Treatment Group 
Next, the cohort of patients was partitioned into the three treatment policies 
mentioned earlier, CD4 < 200, CD4 < 350, and CD4 < 500. The Kaplan-Meier survival 
curves estimated for each treatment group show differences between the distributions of 
patient viral suppression times, given that a patient is assigned to exactly one treatment 
group. The treatment group is time-independent, as it is only affected by when the patient 
entered the cohort, and not on what happens to them as they move through their cascade 
of care. As such, the number at risk will never increase.  
 
Figure 12.  Estimated Survival Function of Viral Suppression Times by 
Treatment Policy with 95% Confidence Intervals (Dotted Lines) 
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Much like the division by treatment, the results of the survival analysis depicted 
in Figure 12 are expected. More inclusive treatment policies (allowing healthier 
individuals to start treatment earlier) increase the probability of reaching viral 
suppression sooner. The following survival tables do not take into account patient’s 
actual starting CD4 values, which are analyzed later, but merely the policy they were 
diagnosed under.  
Table 4.   Estimated Survival Function for Treatment Group 1 
Treat if CD4 < 200 
t n.risk n.event ˆ( )S t  
90 504 20 0.96  
 (0.939 , 0.974) 
180 484 41 0.879  
 (0.847 , 0.905) 
270 443 73 0.734  
 (0.693 , 0.77) 
360 371 31 0.673  
 (0.63 , 0.712) 
450 339 41 0.591  
 (0.547 , 0.633) 
540 298 34 0.524  
 (0.479 , 0.566) 
630 264 31 0.462  
 (0.418 , 0.505) 
720 235 21 0.421  
 (0.378 , 0.464) 
810 214 19 0.384  
 (0.341 , 0.426) 
900 193 15 0.354  
 (0.312 , 0.396) 
990 178 15 0.324  
 (0.284 , 0.365) 
1080 163 15 0.294  
 (0.255 , 0.334) 
1170 148 11 0.272  
 (0.234 , 0.312) 
1260 137 10 0.252  
 (0.215 , 0.291) 
1350 127 11 0.231  
 (0.195 , 0.268) 
1440 116 8 0.215  
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Treat if CD4 < 200 
t n.risk n.event ˆ( )S t  
 (0.18 , 0.252) 
1530 108 9 0.197  
 (0.163 , 0.233) 
1620 99 5 0.187  
 (0.154 , 0.222) 
1710 94 4 0.179  
 (0.147 , 0.214) 
1800 90 6 0.167  
 (0.136 , 0.201) 
 
Table 4 addresses the most restrictive treatment policy. Here, a 90% chance of 
viral suppression is not reached within the given time frame.  
Table 5.   Estimated Survival Function for Treatment Group 2 
Treat if CD4 < 350 
t n.risk n.event ˆ( )S t  
90 348 20 0.943  
 (0.912 , 0.963) 
180 328 119 0.601  
 (0.547 , 0.65) 
270 214 98 0.326  
 (0.277 , 0.375) 
360 113 25 0.254  
 (0.209 , 0.3) 
450 89 22 0.191  
 (0.152 , 0.234) 
540 65 14 0.15  
 (0.115 , 0.189) 
630 51 5 0.135  
 (0.102 , 0.173) 
720 46 7 0.115  
 (0.084 , 0.151) 
810 39 8 0.091  
 (0.064 , 0.124) 
900 31 5 0.076  
 (0.051 , 0.108) 
990 26 2 0.071  
 (0.047 , 0.101) 
1080 24 2 0.065  
 (0.042 , 0.094) 
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Treat if CD4 < 350 
t n.risk n.event ˆ( )S t  
1170 22 3 0.056  
 (0.035 , 0.084) 
1260 19 5 0.041  
 (0.024 , 0.066) 
1350 14 1 0.038  
 (0.021 , 0.062) 
1440 13 2 0.032  
 (0.017 , 0.055) 
1710 11 1 0.029  
 (0.015 , 0.051) 
 
Table 5 shows the estimated survival function of the second treatment group, with 
a policy which was medium-restrictive, performed much better than the first treatment 
group, reaching about 97% chance of viral suppression by t = 20. The confidence 
intervals of both curves do not overlap, showing how different their survival functions 
are.  
Table 6.   Estimated Survival Function for Treatment Group 3 
Treat if CD4 < 500 
t n.risk n.event ˆ( )S t  
90 52 5 0.904  
 
180 47 22 0.481  
 (0.341 , 0.608) 
270 27 14 0.232  
 (0.131 , 0.349) 
360 13 5 0.143  
 (0.066 , 0.247) 
450 7 5 0.041  
 (0.008 , 0.122) 
540 3 1 0.027  
 (0.004 , 0.096) 
 
Table 6 shows the estimated survival function by quarter of the least restrictive 
treatment policy patients. Sample size becomes an issue in this at risk group, as this is the 
most recent policy, with the least amount of accumulated data. This policy, like the 
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second most restrictive policy, reaches about 97% chance of viral suppression by the end 
of the observed periods. However, they reach it much sooner than the medium restrictive 
policy, achieving this low survival function estimate by time t = 6 (540 days).  
3. Survival Analysis by Baseline CD4 
Next, the cohort of patients who were treated was partitioned into the different 
levels of CD4 when treatment began. This grouping variable differs from the treatment 
group variable in that this variable is taken from each patient’s actual baseline CD4 level 
at the start of treatment, regardless of the time or policies in effect when treatment was 
begun. This too is a constant variable, with no time dependency. It is only the patient’s 
initial CD4 measure upon start of ART.  
 
Figure 13.  Estimated Survival Function of Viral Suppression Times by Baseline 
CD4 at Treatment Initiation with 95% Confidence Intervals (Dotted 
Lines) 
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This estimated survival functions in Figure 13 reinforce the point made in the 
earlier analysis by treatment group. Those who start treatment as healthier individuals 
will reach viral suppression faster than those who are already less healthy when they 
begin treatment. However, confidence intervals do overlap often, so a closer look at the 
data is necessary.  
Table 7.   Estimated Survival Function if Baseline CD4 <200 
Base CD4 < 200 
t n.risk n.event ˆ( )S t  
180 29 7 0.759  
 (0.559 , 0.877) 
270 22 10 0.414  
 (0.237 , 0.583) 
360 12 1 0.379  
 (0.209 , 0.549) 
450 11 2 0.31  
 (0.156 , 0.479) 
540 9 1 0.276  
 (0.131 , 0.443) 
630 8 1 0.241  
 (0.107 , 0.405) 
720 7 1 0.207  
 (0.084 , 0.367) 
900 6 1 0.172  
 (0.063 , 0.327) 
1080 5 2 0.103  
 (0.026 , 0.243) 
1350 3 1 0.069  
 (0.012 , 0.198) 
1710 2 1 0.035  
 (0.003 , 0.149) 
1800 1 1 0 
(NA , NA) 
 
In Table 7, patients who started treatment with a baseline CD4 under 200 showed 
strong estimated survival functions throughout the observed time frame. Sample size causes 
issues in this table, as lack of events in certain periods such as t = 9 (810 days) causes those 
periods to be removed from the table. This happens if nobody reaches viral suppression in a 
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given time period, so there is no change in the survival function for that time. These 
individuals reach 0% estimated chance of survival by the end of the observed time.  
Table 8.   Estimated Survival Function if Baseline CD4 200-350 
Base CD4 200-350 
t n.risk n.event ˆ( )S t  
90 184 6 0.967  
 (0.929 , 0.985) 
180 178 45 0.723  
 (0.652 , 0.782) 
270 135 37 0.525  
 (0.45 , 0.594) 
360 97 15 0.444  
 (0.371 , 0.513) 
450 83 18 0.347  
 (0.28 , 0.416) 
540 64 18 0.25  
 (0.19 , 0.314) 
630 46 6 0.217  
 (0.161 , 0.279) 
720 40 6 0.185  
 (0.132 , 0.244) 
810 34 7 0.147  
 (0.1 , 0.202) 
900 27 5 0.119  
 (0.078 , 0.171) 
990 22 2 0.109  
 (0.069 , 0.158) 
1080 20 5 0.081  
 (0.048 , 0.127) 
1170 15 1 0.076  
 (0.044 , 0.12) 
1260 14 1 0.071  
 (0.04 , 0.114) 
1440 13 1 0.065  
 (0.036 , 0.107) 
1530 12 6 0.033  
 (0.013 , 0.066) 
1620 6 1 0.027  
 (0.01 , 0.059) 
1710 5 1 0.022  
 (0.007 , 0.051) 
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As seen in Figure 13 and Table 8, with the increase in baseline CD4, not much 
changes. The estimated survival function is very similar to the first level, however, 
sample size is slightly larger, and so confidence bounds are tighter. Small sample size 
again shows lack of events at certain intervals, leaving out those time periods in the table. 
In the end, the estimated survival function was very similar to that of the first group in 
Figure 13.  
Table 9.   Estimated Survival Function if Baseline CD4 350-500 
Base CD4 350-500 
t n.risk n.event ˆ( )S t  
90 269 13 0.952  
 (0.918 , 0.972) 
180 256 50 0.766  
 (0.711 , 0.812) 
270 207 53 0.57  
 (0.508 , 0.626) 
360 155 20 0.496  
 (0.435 , 0.554) 
450 134 26 0.4  
 (0.341 , 0.458) 
540 107 18 0.333  
 (0.277 , 0.389) 
630 89 17 0.269  
 (0.218 , 0.323) 
720 72 12 0.224  
 (0.177 , 0.276) 
810 60 9 0.191  
 (0.146 , 0.24) 
900 51 6 0.168  
 (0.126 , 0.215) 
990 45 5 0.15  
 (0.11 , 0.195) 
1080 40 5 0.131  
 (0.094 , 0.174) 
1170 35 6 0.108  
 (0.075 , 0.149) 
1260 29 5 0.09  
 (0.059 , 0.128) 
1350 24 6 0.067  
 (0.041 , 0.102) 
1440 18 3 0.056  
 (0.033 , 0.088) 
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Base CD4 350-500 
t n.risk n.event ˆ( )S t  
1620 15 2 0.049  
 (0.027 , 0.079) 
1710 13 1 0.045  
 (0.025 , 0.074) 
1800 12 2 0.037  
 (0.019 , 0.065) 
 
Table 9 shows how the estimated survival function decreases somewhat as CD4 
increases, indicating healthier patients The estimated survival function shows very 
similar results compared to the first two functions.  
Table 10.   Estimated Survival Function if CD4 >500 
Base CD4 500+ 
t n.risk n.event ˆ( )S t  
90 236 12 0.949  
 (0.912 , 0.971) 
180 224 70 0.653  
 (0.588 , 0.71) 
270 156 63 0.389  
 (0.327 , 0.45) 
360 92 18 0.313  
 (0.255 , 0.372) 
450 73 13 0.257  
 (0.203 , 0.314) 
540 60 9 0.219  
 (0.168 , 0.273) 
630 51 8 0.184  
 (0.138 , 0.236) 
720 44 6 0.159  
 (0.116 , 0.209) 
810 37 6 0.133  
 (0.094 , 0.18) 
900 31 5 0.112  
 (0.076 , 0.156) 
990 26 1 0.108  
 (0.072 , 0.151) 
1080 25 2 0.099  
 (0.065 , 0.141) 
1170 23 4 0.082  
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Base CD4 500+ 
 (0.051 , 0.121) 
1260 19 5 0.06  
 (0.035 , 0.096) 
1350 14 3 0.047  
 (0.025 , 0.08) 
1440 11 3 0.034  
 (0.016 , 0.064) 
1530 8 3 0.022  
 (0.008 , 0.047) 
1710 5 1 0.017  
 (0.006 , 0.041) 
1800 4 1 0.013  
 (0.004 , 0.035) 
 
Table 10 indicates that this last group has the healthiest level of patients in the 
cohort. The estimated survival function is slightly better than the previous level, however, 
there is still much overlapping in confidence intervals.  
4. Survival Analysis by Service Community 
Here survival functions are estimated for each service separately. Service is 
another time-independent variable, so no increase in the number at risk is present.  
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Figure 14.  Estimated Survival Function of Viral Suppression Times by Service 
Affiliation with 95% Confidence Intervals (Dotted Lines) 
 
In this case, Figure 14 is not as visually informative as some of its counterparts. 
There is significant overlapping of the survival function estimates between services as 
time progresses, and no survival function estimate stochastically dominates any other. 
Confidence bounds overlap for much of the observed time.  
Table 11.   Estimated Survival Function of Army Patients 
Army 
t n.risk n.event ˆ( )S t  
90 204 7 0.966  
 (0.929 , 0.983) 
180 197 40 0.77  
 (0.706 , 0.822) 
270 158 39 0.58  
 (0.509 , 0.644) 
360 120 20 0.483  
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Army 
t n.risk n.event ˆ( )S t  
 (0.413 , 0.549) 
450 99 12 0.424  
 (0.356 , 0.491) 
540 87 9 0.381  
 (0.314 , 0.446) 
630 78 11 0.327  
 (0.264 , 0.391) 
720 68 9 0.284  
 (0.224 , 0.346) 
810 59 5 0.260  
 (0.202 , 0.321) 
900 53 5 0.235  
 (0.18 , 0.295) 
990 47 3 0.22  
 (0.166 , 0.279) 
1080 44 5 0.195  
 (0.144 , 0.252) 
1170 39 2 0.185  
 (0.135 , 0.241) 
1260 37 3 0.170  
 (0.122 , 0.225) 
1350 34 3 0.155  
 (0.109 , 0.208) 
1440 31 2 0.145  
 (0.101 , 0.197) 
1530 29 4 0.125  
 (0.084 , 0.175) 
1620 25 1 0.12  
 (0.08 , 0.169) 
1710 24 3 0.105  
 (0.068 , 0.152) 
1800 21 1 0.100  
 (0.064 , 0.146) 
 
In Table 11, the Army cohort, the estimated survival function progresses steadily 
downwards, ending up very close to 10%. The cohort experiences the largest drops in 
survival function estimates in the first 4 time periods, losing over 50% of the at risk 
group in this time, while only about 40% drop over the rest of the time period.  
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Table 12.   Estimated Survival Function of Navy Patients 
Navy 
t n.risk n.event ˆ( )S t  
90 415 22 0.947  
 (0.921 , 0.965) 
180 393 82 0.749  
 (0.705 , 0.788) 
270 314 91 0.532  
 (0.483 , 0.579) 
360 222 27 0.468  
 (0.419 , 0.514) 
450 195 39 0.374  
 (0.328 , 0.42) 
540 156 26 0.312  
 (0.268 , 0.356) 
630 129 12 0.283  
 (0.24 , 0.326) 
720 118 11 0.256  
 (0.215 , 0.299) 
810 106 12 0.227  
 (0.188 , 0.269) 
900 94 8 0.208  
 (0.17 , 0.248) 
990 86 8 0.189  
 (0.153 , 0.228) 
1080 78 8 0.169  
 (0.135 , 0.207) 
1170 70 8 0.15  
 (0.118 , 0.186) 
1260 62 7 0.133  
 (0.102 , 0.168) 
1350 55 5 0.121  
 (0.092 , 0.154) 
1440 50 4 0.111  
 (0.083 , 0.144) 
1530 46 2 0.106  
 (0.079 , 0.138) 
1620 44 2 0.102  
 (0.075 , 0.133) 
1800 42 2 0.097  
 (0.071 , 0.128) 
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Table 12 shows Navy patients also reach about 90% chance of viral suppression, 
but confidence intervals overlap with those of the Army patients.  
Table 13.   Estimated Survival Function of Air Force Patients 
Air Force 
t n.risk n.event ˆ( )S t  
90 206 15 0.927  
 (0.882 , 0.955) 
180 191 44 0.714  
 (0.647 , 0.77) 
270 149 43 0.508  
 (0.438 , 0.573) 
360 104 9 0.464  
 (0.395 , 0.53) 
450 95 12 0.405  
 (0.338 , 0.471) 
540 83 7 0.371  
 (0.305 , 0.436) 
630 76 11 0.317  
 (0.255 , 0.381) 
720 65 7 0.283  
 (0.223 , 0.346) 
810 59 6 0.254  
 (0.197 , 0.315) 
900 52 3 0.24  
 (0.184 , 0.3) 
990 49 2 0.23  
 (0.175 , 0.289) 
1170 47 3 0.215  
 (0.162 , 0.274) 
1260 44 4 0.196  
 (0.145 , 0.252) 
1350 40 3 0.181  
 (0.132 , 0.236) 
1440 37 4 0.161  
 (0.115 , 0.215) 
1530 33 2 0.152  
 (0.107 , 0.204) 
1620 31 2 0.142  
 (0.098 , 0.193) 
1710 29 2 0.132  
 (0.09 , 0.182) 
1800 27 3 0.117  
 (0.078 , 0.166) 
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Table 13 shows that the estimated survival function in the Air Force cohort 
decreases slightly faster in times 1-4 than Army and Navy; however, there is again much 
overlapping of confidence intervals, and the Air Force also ends up with around 90% 
chance of viral suppression.  
Table 14.   Estimated Survival Function of Marine Corps Patients 
Marines 
t n.risk n.event ˆ( )S t  
90 79 1 0.987  
 (0.914 , 0.998) 
180 78 16 0.785  
 (0.677 , 0.86) 
270 63 12 0.635  
 (0.52 , 0.73) 
360 51 5 0.573  
 (0.457 , 0.673) 
450 46 5 0.511  
 (0.397 , 0.614) 
540 40 7 0.421  
 (0.312 , 0.527) 
630 33 2 0.396  
 (0.289 , 0.501) 
720 31 1 0.383  
 (0.277 , 0.488) 
810 30 4 0.332  
 (0.231 , 0.436) 
900 26 4 0.281  
 (0.187 , 0.382) 
990 22 4 0.23  
 (0.144 , 0.327) 
1080 18 4 0.179  
 (0.104 , 0.27) 
1170 14 1 0.166  
 (0.094 , 0.256) 
1260 13 1 0.153  
 (0.084 , 0.241) 
1350 12 1 0.14  
 (0.075 , 0.226) 
1530 11 1 0.128  
 (0.066 , 0.211) 
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In Table 14, the Marine Corps cohort, likelihood of viral suppression is much like 
the others. However, the Marine Corps estimated survival function is relatively higher 
throughout the majority of the observed time frame. Confidence intervals are much wider 
due to small sample size, and there is a surprising drop toward the end of the time frame, 
where the Marine Corps catches up to the rest of the cohorts.  
5. Survival Analysis by Number of PCS 
Next, survival functions were estimated as a function of number of PCS. Values 
of PCS ranged from zero, staying in the same location for all 5 years, to 4, moving 4 
times during the 5-year cascade of treatment. However, because there are so few patients 
with more than one move, we combined them into a single group of one or more moves 
(PCS = 1+). This is another time-dependent variable, like treatment. Patients who move 
at least once during treatment switch over to the PCS = 1+ cohort after their move. As 
such, the number of at risk for PCS = 1+ can increase. 
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Figure 15.  Estimated Survival Function of Viral Suppression Times by Number 
of PCS with 95% Confidence Intervals (Dotted Lines) 
 
The trends shown in Figure 15 show very little difference between those who 
moved and those who did not. While it may appear that those who move fare better, the 
uncertainty in this measurement is so large that its confidence bounds encompass the 
estimated survival function of those who did not move.  
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Table 15.   Estimated Survival Function of Patients with No Moves 
PCS = 0 
t n.risk n.event ˆ( )S t  
90 904 45 0.95  
 (0.934 , 0.963) 
180 856 181 0.749  
 (0.72 , 0.776) 
270 634 168 0.551  
 (0.517 , 0.583) 
360 452 53 0.486  
 (0.452 , 0.519) 
450 382 59 0.411  
 (0.378 , 0.444) 
540 313 39 0.36  
 (0.327 , 0.393) 
630 261 28 0.321  
 (0.289 , 0.354) 
720 227 23 0.289  
 (0.258 , 0.321) 
810 195 19 0.261  
 (0.23 , 0.292) 
900 171 16 0.236  
 (0.207 , 0.267) 
990 150 12 0.217  
 (0.188 , 0.248) 
1080 136 13 0.197  
 (0.169 , 0.226) 
1170 118 9 0.182  
 (0.154 , 0.211) 
1260 106 8 0.168  
 (0.141 , 0.197) 
1350 96 7 0.156  
 (0.13 , 0.184) 
1440 86 8 0.141  
 (0.116 , 0.169) 
1530 78 5 0.132  
 (0.108 , 0.159) 
1620 71 2 0.128  
 (0.104 , 0.155) 
1710 69 3 0.123  
 (0.099 , 0.149) 
1800 65 2 0.119  
 (0.095 , 0.145) 
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In Table 15, those patients who did not move reached about 90% chance of viral 
suppression by the end of the observed time.  
Table 16.   Estimated Survival Function l of Patients with 1 Move or More 
PCS = 1+ 
t n.risk n.event ˆ( )S t  
180 3 1 0.667  
 (0.054 , 0.945) 
270 50 17 0.44  
 (0.106 , 0.74) 
360 45 8 0.362  
 (0.099 , 0.64) 
450 53 9 0.3  
 (0.088 , 0.551) 
540 53 10 0.244  
 (0.075 , 0.463) 
630 55 8 0.208  
 (0.066 , 0.404) 
720 55 5 0.189  
 (0.061 , 0.372) 
810 59 8 0.164  
 (0.053 , 0.327) 
900 54 4 0.152  
 (0.05 , 0.305) 
990 54 5 0.138  
 (0.046 , 0.28) 
1080 51 4 0.127  
 (0.042 , 0.26) 
1170 52 5 0.115  
 (0.038 , 0.237) 
1260 50 7 0.099  
 (0.033 , 0.207) 
1350 45 5 0.088  
 (0.03 , 0.186) 
1440 43 2 0.084  
 (0.028 , 0.178) 
1530 41 4 0.075  
 (0.025 , 0.162) 
1620 39 3 0.07  
 (0.023 , 0.151) 
1710 36 2 0.066  
 (0.022 , 0.143) 
1800 35 4 0.058  
 (0.02 , 0.128) 
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Table 16 shows much the same results as in Table 15. The chance of viral 
suppression is almost identical, at t = 20 (1800 days).  
B. MODEL FORMULATION 
In this section, we fit several Cox proportional hazards models to study the 
combined effects of several factors on the survival function.  
1. Model Fitting 
We were unable to fit a single proportional hazards model using all variables. Several 
levels of categorical variables were collapsed due to small sample size. In the rank variable, 
warrant officers were combined with officers, because very few warrant officers appear in the 
data. In the race category, all non-white races were combined into one category, and in the PCS 
category, number of PCS one or more were combined together. Next, non-proportionality was 
accounted for by adding interaction terms to the model. Interactions included age group with 
number of PCS, treatment with time, time treated with treatment group, and treatment group 
with time, and PCS with time. Once the model met proportional hazards assumptions, using 
backward elimination, all variables that were nonsignificant to the regression were removed. 
Some variables were highly correlated to others, so one of them could be removed, such as age, 
since age group already appeared in the model, and ADHERE_95 and ADHERE, because they 
were strongly correlated to the remaining ADHERE_90 variable. Gender was also removed 
from the model, as females account for a small proportion of the data. The final model met 
proportional hazards assumptions globally (p value = 0.965, using Granbsch and Therneau 
(1994) test for proportional hazards), and contained 4 variables: rank, treatment, baseline CD4, 
and treatment group. Treatment and treatment group retained their time interactions in the final 
model.  
2. Interpretation of the Model Coefficients 
Once the final model was fit, the Cox proportional hazards coefficients could be 
interpreted. All coefficients for categorical variables are either calculated with reference 
to the base level of a category, or arbitrarily related to the first level for categorical 
variables. The exponential of the coefficient, θ, gives the percent increase or decrease in 
the likelihood of attaining viral suppression, with reference to the base level of the factor. 
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This means variables with θ greater than 1 show patients with that corresponding trait are 
more likely to reach viral suppression sooner than the baseline. Conversely, variables 
with θ less than 1 indicate patients with that trait are less likely to reach viral suppression 
as soon the baseline, so that trait corresponds to a negative outcome for the patient. 
This model gives a pseudo- R-squared value of 0.242, which is defined as the 
improvement in the model from the null model, where all θ are set to one (Fox and 
Weisberg 2011). Table 17 gives ̂ , estimates of θ, and approximate 95% confidence 
intervals (CI) for θ, where REF indicates the level of the categorical variable for which θ 
is defined to be 1. 
Table 17.   Cox Proportional Hazards Coefficients of the Model 
 ̂  
Lower 95% 
CI for θ 
Upper 95% 
CI for θ  
Rank: Officer REF REF REF 
Rank: Enlisted 0.765 0.636 0.920 
Rank: N/A 1.572 0.996 2.482 
Untreated REF REF REF 
Treated 10.076 3.623 28.024 
Base CD4 < 200 REF REF REF 
Base CD4 200 - 350 0.922 0.721 1.180 
Base CD4 350 - 500 0.888 0.693 1.138 
Base CD4 > 500 1.171 0.916 1.497 
Treat if CD4 < 200 REF REF REF 
Treat if CD4 < 350 1.797 1.394 2.317 
Treat if CD4 < 500 1.789 0.712 4.490 
 
In Table 17, enlisted personnel did significantly worse than officers (p value = 
0.004), and were about 25% less likely to reach viral suppression than officers were. 
Those without an applicable rank did slightly better than officers (p value = 0.052) and 
were about 60% more likely to reach viral suppression. Being treated increased an 
individual’s chances of viral suppression significantly (p value = 0.000). Having a 
baseline CD4 between 200 and 349 did not significantly increase an individual’s chance 
of viral suppression compared to those with baseline CD4 less than 200 (p value = 
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0.520). Those with a baseline CD4 between 350 and 500 were also not significantly 
different (p value = 0.349). Those individuals who had a baseline CD4 above 500 were 
almost 30% more likely to reach viral suppression than those with a baseline CD4 less 
than 200 (̂ = 1.172, C.I. (0.916 , 1.497)). Those in the medium inclusive treatment 
policy were 80% more likely to reach viral suppression than the most restrictive policy (p 
value = 0.000). Those in the least restrictive policy did as well, being almost 80% more 
likely to reach viral suppression than the most restrictive policy, but this improvement 
was not significant at the 5% level of significance.  
C. ATTAINMENT OF 90-90-90 
With the variable of viral suppression available in the final dataset, it was possible to 
determine, of the study population treated, how many of them reached viral suppression. As 
such, the dataset was partitioned to only include treated individuals. One minus the Kaplan-
Meier survival function estimate was used for this cohort, to estimate the cumulative 
distribution function (CDF) for viral suppression time among those who were treated.  
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Figure 16.  Estimated CDF for Viral Suppression Time in Treated Cohort 
From Figure 16, we see that overall, without even taking into account time, changes in 
treatment guidelines, or the other factors in this analysis, the treated military cohort achieved 
about an estimated 99% cumulative probability of viral suppression in this 5-year study 
window. The CDF of the treated cohort’s time to reach viral suppression passed 90% at t = 5 
(450 days).  
1. 90-90-90 by Treatment Group 
The next goal was to take a closer look at how effective the previous treatment 
policies truly were at helping patients reach viral suppression effectively.  
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Vertical line corresponds to time the non-partitioned cohort achieved 90% cumulative 
probability of viral suppression.  
Figure 17.  Estimated CDF for Viral Suppression Time Suppression in Treated 
Cohort, by Treatment Policy 
In Figure 17, all treated cohorts CDFs reach 90% probability of viral suppression 
around the same time. Their confidence bands overlap within the time interval of the 
overall cohort. The mean time to reach viral suppression in the first treatment policy is 
estimated to be 313 days, with a standard error of 13.14 days. The second cohort reached 
viral suppression with an estimated mean of about 258 days, with a standard error of 
8.87, while the most inclusive treatment policy reached viral suppression with an 
estimated mean of about 270 days with a standard error of 35.08 days.  
2. 90-90-90 by Base CD4 
Directly related to treatment policy, of those individuals whose baseline CD4 was 
500 or greater, the CDF of time to reach viral suppression reached 90% sooner than 
 those in the next-healthiest treatment group (Figure 18). This once again suggests that 
more inclusive treatment programs that begin ART sooner in patients, regardless of the 
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relative health of the patient, have much better results, and can aid in reaching 90-90-90 
sooner.  
 
Vertical line corresponds to the time at which the non-partitioned cohort reached 90% 
cumulative probability of viral suppression.  
Figure 18.  Estimated CDF for Viral Suppression Time Suppression in Treated 
Cohort, by Baseline CD4 Count 
In Figure 18, the largest difference in CDF of time to reach viral suppression is 
between the healthiest and second-healthiest patients. The mean time to reach viral 
suppression of those with baseline CD4 greater than 500 is estimated to be 237 days, with 
a standard error of 8.5 days. The second healthiest cohort, with baseline CD4 between 
350 and 500, reached viral suppression with an estimated mean of 278 days, with a 
standard error of 13.1 days.  
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3. 90-90-90 by Service 
Regarding the differences in service affiliation: there were no appreciable 
differences between the services in CDFs of time to reach viral suppression.  
 
Vertical line corresponds to the time at which the non-partitioned cohort reached 90% 
cumulative probability of viral suppression.  
Figure 19.  Estimated CDF for Viral Suppression Time Suppression in Treated 
Cohort, by Service 
In the Figure 19, all treated cohorts of each service have a CDF which reaches 
90% probability of viral suppression around the non-partitioned cohort’s time of 450 
days. The shortest estimated mean time to reach viral suppression was found in the Air 
Force, 247 days with a standard error of 11.9. The longest mean estimated time to reach 
viral suppression was in the Marine Corps, at 298 days with a standard error of 29.5.  
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V. CONCLUSIONS 
A. INITIAL SURVIVAL ANALYSIS 
As shown in Figure 16, the military surpasses 90% cumulative probability of 
reaching viral suppression, thus meeting all three targets of 90-90-90. That treatment has 
a significant impact on the outcome of the patient is a very expected result. From Figure 
11, it is readily apparent that treatment is essential to reaching viral suppression. Those 
who engage in ART are much more likely to reach this positive outcome. However, a 
closer look at the rest of the factors in this analysis may shed some light on less obvious 
results.  
1. Treatment Group 
In this survival analysis, visualized in Figure 12, the two least restrictive policies 
showed decreased probability of remaining non-virally suppressed, while the most 
restrictive group fared much worse. Those patients who were treated when their CD4 was 
500 or less fared much better than those who waited to be treated until their CD4 fell 
below 350 or 200. More inclusive treatment policies mean patients are more likely to 
have a positive outcome. Treating patients regardless of their relative immune system 
strength is a proactive approach which should show better results than previous reactive 
approaches, allowing patients to reach viral suppression much sooner. Figure 17 shows 
that there is not necessarily a perfectly distinguishable relationship between the policies, 
as they all reach 90% cumulative probability of viral suppression around the same time. 
However, the most inclusive treatment policy (treating patients with CD4 < 500) tends to 
reach it first. This is corroborated by international policy, as UNAIDS has stated, 
“Countries will need to align national treatment guidelines with evidence documenting 
the clear benefits of early treatment initiation” (UNAIDS 2014). This cohort confirms the 
necessity and benefits of early treatment initiation, regardless of relative patient health.  
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2. Baseline CD4 
Similarly, those with higher CD4 levels in Figure 13 upon starting treatment tend 
toward viral suppression sooner than those who had lower CD4 levels. However, in 
Figure 18, time to 90% cumulative probability of viral suppression did not display much 
difference by baseline CD4. Increases in baseline CD4 still display decreases in time to 
viral suppression. This concurs with UNAIDS previously mentioned statement, that 
earlier initiation of ART drives progress toward viral suppression.  
3. Service Community 
Service community was not strictly relevant in the survival analysis, and most 
pairwise comparisons between the services were non-significant. The only comparison of 
note was that, on average, the Air Force reached 90% cumulative probability of viral 
suppression sooner, while the Marine Corps reached it later. The lack of strong 
differences between the services agrees with the fact that each service follows the same 
standards of care as released by the NIH.  
B. COX PROPORTIONAL HAZARDS MODEL 
While the Kaplan-Meier model was informative for survival rates between 
different levels of a factor, the Cox proportional hazards model can inform how 
combinations of factors are important to reaching viral suppression.  
1. Rank 
With respect to officers, with all other factors held constant, enlisted personnel 
fare significantly worse in this cohort. Enlisted were 25% less likely to reach viral 
suppression than officers were. Other factors may be at work here, rather than just rank 
disparity, such as risk behaviors, age differences, adherence, and other demographics, but 
such interactions are outside the scope of this analysis.  
2. Treatment 
As already established in the initial survival analysis, individuals who are treated 
do significantly better than those who are not. Even with all other factors the same, those 
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individuals who are treated are 10 times more likely to reach viral suppression than if 
they are untreated. These results agree with UNAIDS policy, which says “the most 
substantial [health and economic] benefits occur when treatment is available to all people 
living with HIV, regardless of CD4 count” (UNAIDS 2014).  
3. Baseline CD4 
With all other factors held constant, compared to the factor level CD4 < 200, 
increasing baseline CD4 to 350, and even 499 has little effect on risk. However, once 
CD4 increases above 500, while not significant at the 95% confidence level in the 
observed time period, individuals are almost 20% more likely to reach viral suppression 
than those whose CD4 is less than 200 at treatment initiation. As stated previously, 
UNAIDS has stressed the importance of initiation of treatment regardless of CD4 count. 
4. Treatment Group 
A steady increase in likelihood of viral suppression can be seen as treatment 
groups become more inclusive. This coincides with the discussion of baseline CD4, as 
UNAIDS has repeatedly said early initiation of ART is key to reaching viral suppression. 
Policies which allow more patients, and healthier patients, to begin treatment early give 
those patients the best chance of reaching good health.  
C. FUTURE WORK 
While the above-mentioned models have provided some useful insights into the 
factors that affect the health of this cohort, some areas can be improved upon or better 
informed with future studies and more rigorous analysis.  
1. Patient Follow-Up and Data Processing 
An area of improvement on this model is finding a way to deal with the patients 
who do not have data for a given time frame, but reappear in the cohort later. Currently, if 
a patient does not have data for a time period, but enters viral suppression in the next, the 
assumption is that they did not reach viral suppression in the previous time period. As 
such, these estimates may be biased toward worse patient performance than what actually 
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occurs. However, without knowledge of these time intervals, assumptions must be made 
to correctly use these survival analysis tools.  
2. Factors of Interest 
The rank factor could be looked at more closely to determine exactly how such a 
factor plays such a significant role in the final model. Interactions with risk behaviors and 
age groups could be considered, as well as analysis of the PCS schedule and adherence 
differences between the groups. Lastly, expanding the data from the current 904 
individuals to include a larger portion of the cohort would be informative. However, it 
would change processing of variables such as treatment group, as older or newer data are 
introduced to the set. 
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